References
- Engeler D, Baranowski AP, Borovicka J, et al. EAU guidelines on chronic pelvic pain. EAU guidelines. Edn. presented at the EAU Annual Congress Copenhagen; 2018. ISBN 978-94-92671-01-1.
- Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20:6759–6773.
- Asano T, Takenaga M. Adenosine A2B receptors: an optional target for the management of irritable bowel syndrome with diarrhea? J Clin Med. 2017;3(6):E104.
- Camilleri M, Oduyebo I, Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am J Physiol Gastrointest Liver Physiol. 2016;311(5):G777–G784.
- Hosseini A, Nikfar S, Abdollahi M. Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther. 2012;12(10):1323–1334.
- O’Mahony SM, Clarke G, Dinan TG, et al. Irritable bowel syndrome and stress-related psychiatric co-morbidities: focus on early life stress. Handb Exp Pharmacol. 2017;239:219–246.
- Mozaffari S, Nikfar S, Abdollahi M. The safety of novel drugs used to treat irritable bowel syndrome. Expert Opin Drug Saf. 2014;13(5):625–638.
- Vasudevan V, Moldwin R. Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome. Asian J Urol. 2017;4:50–54.
- Ha T, Xu JH. Interstitial cystitis intravesical therapy. Transl Androl Urol. 2017;6:S171–79.
- Rourke W, Khan SA, Ahmed K, et al. Painful bladder syndrome/interstitial cystitis: aetiology, evaluation and management. Arch Ital Urol Androl. 2014;86:126–131.
- Patnaik SS, Laganà AS, Vitale SG, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet. 2017;295:1341–1359.
- Gonsior A, Neuhaus J, Horn LC, et al. Interstitial cystitis: diagnosis and pharmacological and surgical therapy. Urologe A. 2017;56:811–827.
- Birder LA, Kullmann FA. Role of neurogenic inflammation in local communication in the visceral mucosa. Semin Immunopathol. 2018;40:261–279.
- Meng E, Hsu YC, Chuang YC. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Low Urin Tract Symptoms. 2018;10:3–11.
- Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–1553.
- Andersson KE, Birder L. Current pharmacologic approaches in painful bladder research: an update. Int Neurourol J. 2017;21:235–242.
- Dellis AE, Papatsoris AG. Bridging pharmacotherapy and minimally invasive surgery in interstitial cystitis/bladder pain syndrome treatment. Expert Opin Pharmacother. 2018 Aug;3:1–5.
- Christianson JA, Liang R, Ustinova EE, et al. Convergence of bladder and colon sensory innervation occurs at the primary afferent level. Pain. 2007;128:235–243.
- Leue C, Kruimel J, Vrijens D, et al. Functional urological disorders: a sensitized defence response in the bladder-gut-brain axis. Nat Rev Urol. 2017;14:153–163.
- Krieger JN, Stephens AJ, Landis JR, et al. Relationship between chronic nonurological associated somatic syndromes and symptom severity in urological chronic pelvic pain syndromes: baseline evaluation of the MAPP study. J Urol. 2015;193:1254–1262.
- Liu S, Hagiwara SI, Bhargava A. Early-life adversity, epigenetics, and visceral hypersensitivity. Neurogastroenterol Motil. 2017;29.
- Jacenik D, Cygankiewicz AI, Fichna J, et al. Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome. Mol Cell Endocrinol. 2018;471:89–96.
- Kumar S, Shukla R, Ranjan P, et al. Interleukin-10: a compelling therapeutic target in patients with irritable bowel syndrome. Clin Ther. 2017;39:632–643.
- Schrepf A, O’Donnell M, Luo Y, et al. Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: associations with painful symptoms. Pain. 2014 Sep;155(9):1755–1761.
- Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152:S2–15.
- Ness TJ, Lloyd LK, Fillingim RB. An endogenous pain control system is altered in subjects with interstitial cystitis. J Urol. 2014;191:364–370.
- Martinez-Martinez LA, Mora T, Vargas A, et al. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis. A review of case-control studies. J Clin Rheumatol. 2014;20:146–150.
- Fan Y-H, Lin ATL, Lu S-H, et al. Non-bladder conditions in female Taiwanese patients with interstitial cystitis/hypersensitive bladder syndrome. Int J Urol. 2014;21:805–809.
- Logadottir Y, Delbro D, Fall M, et al. Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C. J Urol. 2014;192:1564–1568.
- Chatoo M, Li Y, Ma Z, et al. Involvement of corticotropin-releasing factor and receptors in immune cells in irritable bowel syndrome. Front Endocrinol (Lausanne). 2018;9:21.
- Borchert DH, Sheridan E, Papatsoris A, et al. The case for probiotics in urology. BJU Int. 2008;101(4):413–414.
- Barbara G, Cremon C, Azpiroz F. Probiotics in irritable bowel syndrome: where are we? Neurogastroenterol Motil. 2018 Dec;30(12):e13513.
- Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine. 2017;99:132–138.
- Nickel JC, Irvine-Bird K, Jianbo L, et al. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(1):175–179.
- Dellis A, Papatsoris AG. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections. Expert Opin Investig Drugs. 2014;23(6):751–757.
- Ogawa T, Ishizuka O, Ueda T, et al. Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). Expert Opin Emerg Drugs. 2015;20(4):–555–70.